Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

Integrated Biopharma Q1 2026 Results: Net Loss of $691K

Integrated BioPharma reported a net loss of $691,000 for the quarter ended September 30, 2026, compared to a net income of $123,000 in the prior year period, driven by a significant decline in net sales from $12.7 million to $9.9 million. The company experienced a gross loss of $112,000 as cost of sales exceeded revenue, leading to a basic and diluted net loss of $0.02 per share.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Revenue9.912.7
Gross profit-0.11.0
Profit before tax-0.90.2
Net income-0.70.1
EPS (diluted, $ a share)$-0.02$0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-21.9%
Gross margin-1.1%
Operating margin-9.7%
Source

10-Q filed with the SEC, OTC: INBP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Integrated Biopharma Inc: key numbers

Share price
$0.1800Close, Nov 16
Market cap
$5.59M
Shares outstanding
31.06MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Integrated Biopharma Inc

All →
12:12 PM ET 8-K
Financial Results

Integrated Biopharma Financial Results

Integrated BioPharma reported a 22% revenue decline to $9.9 million for the quarter ended September 30, 2026, resulting in a net loss of $0.7 million. The company noted significant customer concentration, with its two largest contract manufacturing clients accounting for 88% of total revenue.

Term
Q1 2027

“Our revenue decreased by approximately 22% in the quarter ended September 30, 2026 from the quarter ended September 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 88% and 87% of total revenue in the quarters ended September 30, 2026 and 2025, respectively.”

Riva Sheppard and Christina Kay, Co-Chief Executive Officers
5:08 PM ET 8-K
Financial Results

Integrated Biopharma Financial Results

Integrated BioPharma reported financial results for its fiscal year ended June 30, 2026, showing a 19.3% revenue decrease to $43.9 million. The company swung to a net loss of $2.8 million ($0.09 per share) compared to a net income of $0.8 million in the prior fiscal year, driven by lower sales and an operating loss of $2.7 million.

Term
FY2026

“Our revenue decreased by approximately 19% in our fiscal year ended June 30, 2026 from the fiscal year ended June 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 90% and 84% of total revenue in our fiscal years ended June 30, 2026 and 2025, respectively.”

Riva Sheppard and Christina Kay, Co-Chief Executive Officers

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.